Modest Covid Impact; Encouraging Revenue Opportunities

Friday, May 15, 2020

Harte-Hanks Inc. (HHS)

Modest Covid Impact; Encouraging Revenue Opportunities

Harte-Hanks is a marketing services company that provides multichannel marketing solutions as well as consulting, data analytics, and strategic assessment. The company’s offerings focus on business-to-business, retail, finance, and automotive segments through digital, social, mobile, and print media offerings. Harte-Hanks strives to develop better customer relationships through its marketing and analytical services for clients. The majority of its revenue is derived from its marketing services in the retail, technology, and consumer brand segments.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Beats on revenue. Q1 revenues of $40.5 million was better than our $39.5 million estimate, in spite of the Covid impact, estimated to have adversely affected revenues by $2 million. Costs were a little higher than expected, and, as such, adj. EBITDA was shy of our loss of $1.7 million, coming in at a loss of $2.4 million.

    Encouragingly, maintaining quarterly outlook. The Covid impact appears to be relatively modest, hitting its marketing services business, but not its contact center or market fulfillment businesses. Our revenue estimates have been adjusted for the exit of its direct mail operations to Summit Direct Mail, which will save $2 million to $3 million in annualized savings. Adj. EBITDA is expected to be positive in coming quarters for…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Brushing Off Covid

Friday, May 15, 2020

QuoteMedia (QMCI)

Brushing Off Covid

QuoteMedia, based in Fountain Hills, Arizona, provides cloud-based financial data, market news feeds, and financial software solutions.  Its customers include financial service companies, online brokerages, clearing firms, banks, media portals, public corporations and individual investors.  The company provides a single source solution providing products such as streaming quotes, charting, historical data, technical analysis, news and research.  Information can customized and provided to multiple platforms including terminals and mobile devices.

Michael Kupinski, DOR, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Solid Q1. First quarter results were largely in line with expectations in spite of Covid 19 that wrecked the economy and many businesses. Revenues increased 3.3%, in line with our expectations. Adj. EBITDA was lower, $191,000 versus our $414,000 estimate, largely due to investments into new products that are expected to be rolled out in

    Management clearly was hoping for a better quarter. The company was impacted by Covid as some clients paused services and some even shuttered. Even though companies appear more cautious, Quotemedia appears to be benefiting from a shift toward work from…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Phase I Results at ASCO Bode Well for Lead Drug’s Prospects

Friday, May 15, 2020

Helix Biopharma (HBPCF)(HBP:CA)

Phase I Results at ASCO Bode Well for Lead Drug’s Prospects

As of April 24, 2020, Noble Capital Markets research on Helix Biopharma is published under ticker symbols (HBPCF and HBP:CA). The price target is in USD and based on ticker symbol HBPCF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Helix BioPharma Corp is a Canada-based clinical-stage biopharmaceutical company focused on cancer drug development. It develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. The company has Tumor Defense Breakers (L-DOS47), and Tumor Attackers (CAR-T) product candidates in the pipeline.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Helix Biopharma presents data at ASCO 2020. Helix BioPharma yesterday announced results from a recently completed Phase I dose escalation clinical trial on the use of L-DOS47, in combination with pemetrexed and carboplatin, for the treatment of a type of lung cancer. The results were published by American Society of Clinical Oncology (ASCO).

    Lead drug L-DOS47 shows clinical benefit. Of the twelve patients evaluable for efficacy, 5 patients (42%) had a partial response to treatment, 4 patients (33%) showed stable disease and three patients (25%) had progressive disease. In the trial, the objective response rate was 42% and…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Sierra Metals (SMTS)(SMT:CA) – The Benefits of a Growing Production Profile

Friday, May 15, 2020

Sierra Metals (SMTS)(SMT:CA)

The Benefits of a Growing Production Profile

As of April 24, 2020, Noble Capital Markets research on Sierra Metals is published under ticker symbols (SMTS and SMT:CA). The price target is in USD and based on ticker symbol SMTS. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    First quarter earnings. Sierra Metals reported adjusted earnings per share of $0.01 compared with $0.01 during the prior year period and our estimate of $0.00. Adjusted EBITDA of $16.1 million increased 34.2% compared with the prior year period and exceeded our estimate. Overall, the company performed well both operationally and financially given challenges arising from the onset of COVID-19 work restrictions in March.

    Updating estimates. While we trimmed our second quarter EPS estimate to reflect modestly higher expense, our full year EPS estimate remains $0.05. We forecast 2020 EBITDA estimate of $64.4 million. Our 2021 estimates remain…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

The Benefits of a Growing Production Profile

Friday, May 15, 2020

Sierra Metals (SMTS)(SMT:CA)

The Benefits of a Growing Production Profile

As of April 24, 2020, Noble Capital Markets research on Sierra Metals is published under ticker symbols (SMTS and SMT:CA). The price target is in USD and based on ticker symbol SMTS. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    First quarter earnings. Sierra Metals reported adjusted earnings per share of $0.01 compared with $0.01 during the prior year period and our estimate of $0.00. Adjusted EBITDA of $16.1 million increased 34.2% compared with the prior year period and exceeded our estimate. Overall, the company performed well both operationally and financially given challenges arising from the onset of COVID-19 work restrictions in March.

    Updating estimates. While we trimmed our second quarter EPS estimate to reflect modestly higher expense, our full year EPS estimate remains $0.05. We forecast 2020 EBITDA estimate of $64.4 million. Our 2021 estimates remain…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Millennials Could Use Help With Investing

Investment Portfolios are Checked Twice as Often by Millennials

The needs of younger adults are often overlooked by investment professionals. Despite the younger generation’s size, high education, and earning power, the efforts of financial professionals remain focused on those closer to the end of their lives, while paying less attention to those on the way up. Millennials and the Generation that followed (Gen Z) are both at stages in their adulthood where they have assets they’re trying to maximize. The assets may not yet be as large as those in or near retirement, so far fewer investment professionals focus on serving them.

These younger investors came of age at a time where they witnessed the stock market grow at a historic pace to record levels. For more than a decade, they experienced a bull market like no other; now, they’re experiencing something new. They’re rightfully concerned about the realities of investing. In fact, there is evidence that they are more concerned about their investment accounts than their monthly income or their health.

In a press release earlier this month, E*TRADE revealed surprising survey data captured on their quarterly tracking study of experienced investors. The research found that Gen Z and Millennials (adults 30 and under) have become very concerned about investing since the beginning of the pandemic crisis.

Findings
in Tracking Study

The findings show that investors in this age group with accounts of $10,000 or more will check the value of their accounts twice as often as older investors. It’s evident from the report that providers of information to investors, including advisors, investment platforms, and financial publications, may want to expand their focus. The main points from the release are below.

  • Portfolio
    concerns surpass health worries
     – Investors under 30 say their number one concern during the COVID-19 crisis is their investment portfolio (53%), followed by their health (44%), and then their ability to afford day-to-day living expenses (43%).

 

  • They
    are checking their portfolio much more often than other generations
     –More than half of investors under 30(54%) check their portfolio at least daily, compared to 29% of the total population. In fact, almost three out of five investors under 30 (58%) say they check their portfolios more frequently since the coronavirus pandemic.

 

  • Confidence remains, albeit slightly reduced – Nearly three out of five young investors (59%) remain confident they’re making the right decisions for their portfolios, compared to 38% of the total population. Confidence has dipped seven and 10 percentage points since the survey last quarter among young investors and the total population, respectively.

 

 

 

Dealing With
Volatility

It’s understandable to hear portfolio concerns in this market. Even investors that have experienced volatility in their accounts during other crises are likely to be monitoring their positions more closely. Fortunately, time is on the side of those that are younger, but it’s still very disconcerting to be looking at the balance one day, then a week later, find it to be 20%-30% lower.

In some cases, it may be that a voice of experience and better understanding of stock market history may be helpful to get younger investors to feel more confident. In other cases, it may be best for an investor (of any age) to leave it to a trusted professional to look after.

In the press release, Mike Loewengart, Chief Investment Officer,  E*TRADE Capital Management,  is quoted as saying, “Those who are concerned about market volatility should remain grounded in their financial goals, keep their eyes on the long term, and stay diversified. While these are no doubt unsettling times, they will run their course.”

Mr. Loewengart and the E*TRADE release also offered these suggestions to young investors concerned about their portfolio in the current environment:

  • The
    market doesn’t move in one direction. 
    It makes sense seeing skittish behavior in the current environment. Although this was the quickest sell-off since the Great Depression, the S&P 500 is still up significantly from where it was even just five years ago—suggesting the importance of keeping a long-term view.

 

  • Don’t
    attempt to time the market. 
    Chasing performance is a risky business—you’re always looking in the rear-view mirror. While historical data can be helpful, it bears repeating that past performance does not guarantee future results. What goes down hard can come up strong and vice versa. A solid example is April’s impressive rally from the March low. If investors had fled the exits at the bottom, they would have missed out on those gains. Stay committed to the portfolio you’ve worked so hard to build.

 

  • Diversification
    proves its mettle in this environment. 
    In times of extreme market volatility, a balanced portfolio can help you ride out market swings. As earnings season continues, it’s becoming clearer that the pandemic is not hurting all sectors equally—consumer staples and health care are thriving. A simple way to participate in the market’s various sectors is to be broadly exposed, which one can achieve through such instruments as index ETFs or mutual funds.

Unsupported image type.

 

Take-Away

Although we tend to equate stock market investing with an older graying population, Gen Z and Millennials are all adults and represent the largest living generation. The age-group is at a stage where they’re developing and implementing their financial plans and are concerned. They’ve witnessed a long bull run, so they know the benefits of investing, however, experience has not prepared them for the current gyrations. Learning by mistakes is normal, but when they are financial mistakes such as selling too soon, taking on too much or too little risk, or poor allocations, the mistakes may be detrimental as they could severely impact plans for the future.

In another article published on Channelchek earlier this year, it was discussed that younger investors are more likely to understand regularly scheduled saving. They also tend to be less interested in owning a home, and may not have work-sponsored retirement plans because a higher percent are part of the gig economy. It’s clear that service providers can do more to support and provide information and advice to this age group.

It was unclear from the press release if the “E*TRADE Baby,” now 14, is still killing it with his investments.

 

Paul Hoffman

Managing Editor

 

Suggested Reading:

The
9 Paradigm Shifts Investment Professionals Can’t Ignore in the New Decade

Stock
Index Adjustments and Self-Directed Investors

Where
Investors Found Double-Digit Growth in the First Quarter

 

Enjoy Premium Channelchek Content at No Cost

 

Sources:

Investment Concerns Overshadow Health and Daily Expenses Amid Pandemic

E*TRADE Newsroom

A Guide to Millennial Investing (Bankrate)

 

Photo: Business
Wire

Building on Momentum

Thursday, May 14, 2020

Ely Gold Royalties (ELYGF)(ELY:CA)

Building on Momentum

As of April 24, 2020, Noble Capital Markets research on Ely Gold Royalties is published under ticker symbols (ELYGF and ELY:CA). The price target is in USD and based on ticker symbol ELYGF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ely closes on purchase of second producing royalty at Jerritt Canyon. Ely Gold announced that it has completed the purchase agreement of a 0.5% net smelter returns royalty on the Jerritt Canyon mine, located near Elko, Nevada. Royalty payments began to accrue in February 2020. Ely Gold also holds a per ton royalty interest on the Jerritt Canyon processing facilities and a 0.75% producing royalty on the Isabella Pearl mine operated by Gold Resource Corp.

    Ely graduates to the OTCQX. Ely Gold upgraded to the OTCQX Best Market from the OTCQB Venture Market and began trading on May 12, 2020 under the symbol “ELYGF.” Because listing requirements are more stringent, graduating to the OTCQX market is expected to enhance the company’s visibility among U.S. investors and liquidity. Ely also trades on the…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Q1 Highlighted by Foray into Infectious Diseases Area

Thursday, May 14, 2020

PDS Biotechnology Corp (PDSB)

Q1 Highlighted by Foray into Infectious Diseases Area

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1/F2020 Financial Results in line with our expectations.PDS Biotechnology yesterday announced financial results for Q1/F2020. The Company reported a net loss of $4.0 mm, or $0.39 per basic share and fully diluted share. In our view, the highlight of the quarter was the expansion of the Company’s product pipeline into infectious diseases. Now, PDS has Versamune vaccine programs in cancer, tuberculosis, influenza and COVID-19.

Versamune is a versatile vaccine platform technology.The Company is developing a platform technology known as Versamune, which consists of lipid nanoparticles designed to deliver disease-specific antigens to stimulate a potent immune response consisting of both humoral (antibodies) and cellular immunity. Versamune has potential applications for the treatment of cancer and…



Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Ely Gold Royalties (ELYGF)(ELY:CA) – Building on Momentum

Thursday, May 14, 2020

Ely Gold Royalties (ELYGF)(ELY:CA)

Building on Momentum

As of April 24, 2020, Noble Capital Markets research on Ely Gold Royalties is published under ticker symbols (ELYGF and ELY:CA). The price target is in USD and based on ticker symbol ELYGF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ely closes on purchase of second producing royalty at Jerritt Canyon. Ely Gold announced that it has completed the purchase agreement of a 0.5% net smelter returns royalty on the Jerritt Canyon mine, located near Elko, Nevada. Royalty payments began to accrue in February 2020. Ely Gold also holds a per ton royalty interest on the Jerritt Canyon processing facilities and a 0.75% producing royalty on the Isabella Pearl mine operated by Gold Resource Corp.

    Ely graduates to the OTCQX. Ely Gold upgraded to the OTCQX Best Market from the OTCQB Venture Market and began trading on May 12, 2020 under the symbol “ELYGF.” Because listing requirements are more stringent, graduating to the OTCQX market is expected to enhance the company’s visibility among U.S. investors and liquidity. Ely also trades on the…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

PDS Biotechnology Corp (PDSB) – Q1 Highlighted by Foray into Infectious Diseases Area

Thursday, May 14, 2020

PDS Biotechnology Corp (PDSB)

Q1 Highlighted by Foray into Infectious Diseases Area

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1/F2020 Financial Results in line with our expectations.PDS Biotechnology yesterday announced financial results for Q1/F2020. The Company reported a net loss of $4.0 mm, or $0.39 per basic share and fully diluted share. In our view, the highlight of the quarter was the expansion of the Company’s product pipeline into infectious diseases. Now, PDS has Versamune vaccine programs in cancer, tuberculosis, influenza and COVID-19.

Versamune is a versatile vaccine platform technology.The Company is developing a platform technology known as Versamune, which consists of lipid nanoparticles designed to deliver disease-specific antigens to stimulate a potent immune response consisting of both humoral (antibodies) and cellular immunity. Versamune has potential applications for the treatment of cancer and…



Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

The Fed’s Power and Impact are Again Tested

Will the Fed “Put” Become Worthless?

At some point during Alan Greenspan’s long reign as Federal Reserve chairman (1987-2006), the term “Greenspan Put” was coined. The term refers to the Fed, under Greenspan, and their maintenance of an easy monetary policy that was conducive to economic growth and offered protection against volatile price swings in the stock market.

  In 2006 Ben Bernanke replaced Greenspan as Chairman of the Federal Reserve Bank. He continued many of the policies of his predecessor through the end of his second term (2014). This lead to lower and lower interest rates, while inflation was maintained within an acceptable range. The policy of managing the economy for growth to help limit the risk of the stock market then became the “Bernanke Put.”

Interest rate quarterly on USTN 10 yr., since 1979.  Source: St. Louis Fed Data

Economic growth was certainly a challenge during the periods the two chairmen had their hands on steering Fed policy. Greenspan dramatically intervened during the savings and loan crisis, the Asian crisis, the Gulf War, and the Long-Term Capital crisis. He also managed the “irrational exuberance” of the dot.com bubble and the risks surrounding Y2K. Bernanke, for his part, continued to ease policy through the final two years of President Bush’s time in office. This included the beginning of the 2008 financial crisis. During this time, the Fed’s easing quickly brought overnight rates to near 0%. This left them with no room to stimulate by lowering the key interest rate. This is when the Fed, under Bernanke, began a program they referred to as Quantitative easing (QE).  QE increased the supply of money into the economy by $4 trillion.

Unsupported image type. 

 

 

 

Chairman Janet Yellen replaced Ben Bernanke and continued the “safety net” policies of impacting bond market prices to prevent the economy from softening. This period included the longest bull market in U.S. history.

Is There
a Powell Put?

Is Fed Chairman Jerome Powell continuing the safety net role the Fed implemented 40 years ago by the “The Great Maestro” Chairman Greenspan? Although not challenged like his predecessors had been until the global economic derailing earlier this year, Powell has moved quickly to drop rates to near-zero levels by targeting the overnight bank lending rate and purchasing Treasuries and mortgage securities. His actions have flattened the yield curve and provided massive amounts of “new money” into the system.

On Monday (5/11) the Fed announced it would take a step never before tried. It informed the markets it would begin purchasing corporate bonds via fixed-income ETFs. The purpose is to help companies borrow in the capital markets and at the same time, add cash into the system.  At a press conference yesterday (5/13), Chairman Powell spoke of the need to use forceful policies to avert dire consequences from the historic downturn. He warned the United States is experiencing an economic hit “without precedent.”  A situation so dire, it could permanently damage the economy if Congress and the White House did not provide sufficient financial support to prevent prolonged joblessness and bankruptcies.

As Chairman Powell expressed approval of the $2 trillion in relief Congress had already funded, he made clear the rebound would not be quick and could take months to materialize. Powell recommended more support to take the country past this hardship.

Take-Away

The stock market and others that benefit from a rebound in the economy can take some comfort that Federal Reserve Chairman Powell will also do everything in the Feds power to provide downside protection. It is unclear whether confidence in the “Powell Put” will continue to prop up stock prices. What has become clear, however, is that over the past 40 years,  the resolve of the Fed has not weakened.

 

Suggested
Reading:

Climbing a Wall of Worry

Feds Bond ETF Purchases Will Impact
Equity Investors

Why Index Funds Could Be a Mistake in
2020

Enjoy Premium
Channelchek Content
 at No Cost

 

Sources:

Greenspan Put

Stocks Fall as
Powell Warns of Lasting Economic Damage

Bernanke Put

Gevo, Inc. (GEVO) – Wider Quarterly Loss, But Cost Cuts Are Positive

Wednesday, May 13, 2020

Gevo, Inc. (GEVO)

Wider Quarterly Loss, But Cost Cuts Are Positive

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment and the Gevo Development/Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of isobutanol, including the development of its biocatalysts, the production and sale of biojet fuel, its Retrofit process and the next generation of chemicals and biofuels that will be based on its isobutanol technology. Gevo Development/Agri-Energy is the key revenue generating segment which involves the operation of the Luverne Facility and production of ethanol, isobutanol and related products.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Wider 1Q2020 loss, but 2020 estimated EBITDA losses narrowed to $14.4 million due to idling of Luverne plant in response to ethanol market weakness. Adjusted 1Q2020 EBITDA of $(6.3)

    million was wider than $(4.0) million in 4Q2019 due to weaker ethanol market. Luverne plant idling reduces operating losses and improves cost structure to push quarterly cash burn down below the $4 million range.

    Solid progress on Phase 1 goal of lower carbon intensity. Luverne plant idled for foreseeable future, but no change in near-term strategy. Wind energy is now in place and biogas strategy continues with build out of renewable natural gas (RNG) production. Phase 2 expansion backed by existing supply portfolio. Supply agreements of 17 million gallons/year in place (valued at $600 million) and potential supply agreements in the up to 70 million gallons/year range (~$1.5 billion of added value) are ongoing despite the current turmoil in the airline/refining industries. Interest in commercializing the concept remains high and industry partners could be added shortly. Potential expansion plans include retro-fitting two other existing ethanol plants and…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Strong 1Q20 Results

Wednesday, May 13, 2020

Vectrus (VEC)

Strong 1Q20 Results

Vectrus Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offer facility and logistics services and information technology and network communications services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations and others.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    1Q20. Revenue of $351.7 million, up 7.9% y-o-y. Consensus was $337 million and we were at $350 million. EPS was $0.74, up from $0.62 in 2019. Consensus was $0.74 and we were at $0.69. Organic revenue growth was 4% and Advantor added $11.2 million. Management estimated COVID impacted revenue by $2.2 million and EPS by $0.02 in the quarter.

    Revenue Up in all Geographies and with all Major Customers. Revenue in Europe grew 15% to $32.3 million, U.S. by 14% to $81.4 million, and 5% in the Middle East to $237.9 million. Revenue from the Army grew 9.2% to $247.6 million. The Air Force was up 8% to $73.3 million, and Navy revenue rose 1.0% to $15.2 million. The Company’s focus on enhancing its portfolio of clients and…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.